---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-004247"
form_type: "8-K"
ticker: null
cik: "0001173281"
company_name: "NeuBase Therapeutics, Inc."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:26:51.275927+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuBase terminates CEO Dietrich Stephan; appoints CFO Todd Branning as interim CEO

## Summary
- Board terminated Dietrich A. Stephan as CEO without cause, effective Jan 16, 2024.
- Todd P. Branning, CFO since Jan 2022, appointed interim CEO, retaining CFO role.
- Dr. Stephan expected to continue serving on the Board.
- Branning's compensation unchanged as a result of the appointment.
- No family relationships or material transactions with Branning disclosed.

## SEC filing metadata
- accession: 0001104659-24-004247
- form_type: 8-K
- cik: 0001173281
- company_name: NeuBase Therapeutics, Inc.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/0001104659-24-004247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/tm243413d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-004247
- JSON: https://secwatch.observer/filing/0001104659-24-004247.json
- Plain text: https://secwatch.observer/filing/0001104659-24-004247.txt

## Key facts
- Executive change
  Todd P. Branning was appointed as interim Chief Executive Officer at NeuBase Therapeutics, Inc..
  - Action: appointed
  - Role: interim Chief Executive Officer
  source text: appointed Todd P. Branning, who has served as the Company’s Chief Financial Officer since January 2022, as the Company’s interim Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/0001104659-24-004247-index.htm
- Executive change
  Dietrich A. Stephan was terminated as Chief Executive Officer at NeuBase Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Executive Officer
  source text: terminated the employment of Dietrich A. Stephan, Ph.D. as Chief Executive Officer of the Company, without cause
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/0001104659-24-004247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.